CTOs on the Move

ParaPRO

www.parapro.com

 
ParaPRO is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.parapro.com
  • 11550 N Meridian St Ste 600
    Carmel, IN USA 46032
  • Phone: 317.428.4597

Executives

Name Title Contact Details

Similar Companies

Hi-Tech Pharmacal Co Inc

Hi-Tech Pharmacal Co Inc is a Amityville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Breas Medical

Breas was founded in 1991 in Gothenburg, Sweden and has become one of the global leaders in Home Mechanical Ventilation, Airway Clearance and Sleep therapy.

Recursion

Recursion is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a massively parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease. Recursion applies causative perturbations to human cells to generate disease models and associated biological image data. Recursion`s rich, relatable database of more than a petabyte of biological images generated in-house on the company`s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics to radically improve lives. Recursion is headquartered in Salt Lake City.

Maruho Medical

We are focused on improving sports medicine outcomes by providing innovative technologies and supporting surgeons with integrity, collaboration, and a commitment to excellence. We achieve this by providing medical devices and services that are unique, highly effective, reliable, easy to learn and cost-effective. At present, maruho medical offers a comprehensive portfolio of orthopedic surgery products that complement arthroscopic shoulder, knee, hip, and extremity procedures.

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).